BR112012031861A2 - uso de 5a-androstano (alquil)-3b, 5, 6b-triol - Google Patents

uso de 5a-androstano (alquil)-3b, 5, 6b-triol

Info

Publication number
BR112012031861A2
BR112012031861A2 BR112012031861A BR112012031861A BR112012031861A2 BR 112012031861 A2 BR112012031861 A2 BR 112012031861A2 BR 112012031861 A BR112012031861 A BR 112012031861A BR 112012031861 A BR112012031861 A BR 112012031861A BR 112012031861 A2 BR112012031861 A2 BR 112012031861A2
Authority
BR
Brazil
Prior art keywords
androstane
triol
alkyl
Prior art date
Application number
BR112012031861A
Other languages
English (en)
Other versions
BR112012031861B1 (pt
Inventor
Guangmei Yan
Haiyan Hu
Hanfei Sang
Jiesi Chen
Jingxia Zhang
Pengxin Qiu
Shujia Zhou
Tiandong Leng
Xiuhua You
Original Assignee
Guangzhou Cellprotek Pharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Cellprotek Pharmaceutical Ltd filed Critical Guangzhou Cellprotek Pharmaceutical Ltd
Publication of BR112012031861A2 publication Critical patent/BR112012031861A2/pt
Publication of BR112012031861B1 publication Critical patent/BR112012031861B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0007—Androstane derivatives not substituted in position 17

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
BR112012031861A 2010-07-09 2011-07-08 uso de 5a-androstano-3ß,5,6ß-triol BR112012031861B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2010102241733A CN101884638B (zh) 2010-07-09 2010-07-09 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用
PCT/CN2011/076967 WO2012003802A1 (zh) 2010-07-09 2011-07-08 5α-雄甾（烷）-3β，5，6β-三醇在制备神经元保护药物中的应用

Publications (2)

Publication Number Publication Date
BR112012031861A2 true BR112012031861A2 (pt) 2016-11-08
BR112012031861B1 BR112012031861B1 (pt) 2020-02-04

Family

ID=43070839

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012031861A BR112012031861B1 (pt) 2010-07-09 2011-07-08 uso de 5a-androstano-3ß,5,6ß-triol

Country Status (21)

Country Link
US (2) US8809309B2 (pt)
EP (1) EP2591785B1 (pt)
JP (1) JP5681931B2 (pt)
KR (1) KR101463477B1 (pt)
CN (1) CN101884638B (pt)
AU (1) AU2011276800B2 (pt)
BR (1) BR112012031861B1 (pt)
CA (1) CA2802133C (pt)
CY (1) CY1118789T1 (pt)
DK (1) DK2591785T3 (pt)
ES (1) ES2620754T3 (pt)
HR (1) HRP20170418T1 (pt)
HU (1) HUE032159T2 (pt)
LT (1) LT2591785T (pt)
PL (1) PL2591785T3 (pt)
PT (1) PT2591785T (pt)
RS (1) RS55845B1 (pt)
RU (1) RU2541093C2 (pt)
SG (1) SG186135A1 (pt)
SI (1) SI2591785T1 (pt)
WO (1) WO2012003802A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101884638B (zh) * 2010-07-09 2011-11-09 中山大学 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用
CN101961311B (zh) * 2010-09-21 2012-11-21 中山大学 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法
CN105012313B (zh) * 2014-04-25 2018-03-16 广州市赛普特医药科技股份有限公司 5α‑雄甾‑3β,5,6β‑三醇及其类似物在预防或治疗低压缺氧引起的高原病中的应用
CN103626819B (zh) * 2012-03-08 2016-01-20 广州市赛普特医药科技有限公司 雄甾-3β,5α,6β-三醇的晶型化合物及其制备方法
EP2653163A1 (en) * 2012-04-19 2013-10-23 Université de Liège Estrogenic components for use in the treatment of neurological disorders
CN104072564B (zh) * 2013-03-28 2016-08-17 广州市赛普特医药科技股份有限公司 2β,3α,5α-三羟基-雄甾-6-酮及其制备方法与用途
CN113350359B (zh) * 2017-12-29 2022-08-16 广州市赛普特医药科技股份有限公司 5α-雄甾-3β,5,6β-三醇在制备治疗出血性脑卒中药物中的应用
CN109985049B (zh) 2017-12-29 2022-02-22 广州市赛普特医药科技股份有限公司 5α-雄甾-3β,5,6β-三醇在制备治疗脑小血管病的药物中的应用
US11516173B1 (en) * 2018-12-26 2022-11-29 Snap Inc. Message composition interface

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2191576A (en) * 1936-11-21 1940-02-27 Soc Of Chemical Ind 3,5,6-trihydroxy androstane and pregnane compounds
US6046185A (en) * 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
US20030060425A1 (en) * 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
EP1689767A1 (en) * 2003-11-24 2006-08-16 Merck & Co., Inc. Estrogen receptor modulators
CN1557829A (zh) * 2004-01-19 2004-12-29 复旦大学 化合物5α-雄甾烷-1α,3β,17β-三醇17-醋酸酯和衍生物,及其制备方法
US8354396B2 (en) * 2006-11-17 2013-01-15 Harbor Therapeutics, Inc. Drug identification and treatment method
GB0711948D0 (en) 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
CN101683348B (zh) * 2008-09-23 2012-07-04 中山大学 胆甾烷-3β,5α,6β-三醇在制备神经元保护药物中的应用
CN101884638B (zh) 2010-07-09 2011-11-09 中山大学 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用
CN101961311B (zh) * 2010-09-21 2012-11-21 中山大学 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法

Also Published As

Publication number Publication date
WO2012003802A1 (zh) 2012-01-12
SG186135A1 (en) 2013-01-30
PL2591785T3 (pl) 2017-08-31
RS55845B1 (sr) 2017-08-31
CN101884638B (zh) 2011-11-09
RU2012151400A (ru) 2014-08-20
LT2591785T (lt) 2017-06-26
EP2591785A4 (en) 2013-12-11
HUE032159T2 (en) 2017-09-28
JP5681931B2 (ja) 2015-03-11
CY1118789T1 (el) 2018-03-07
BR112012031861B1 (pt) 2020-02-04
KR20130038286A (ko) 2013-04-17
AU2011276800A9 (en) 2013-11-21
EP2591785B1 (en) 2017-01-04
AU2011276800B2 (en) 2013-11-21
SI2591785T1 (sl) 2017-07-31
HRP20170418T1 (hr) 2017-06-16
KR101463477B1 (ko) 2014-11-19
CN101884638A (zh) 2010-11-17
ES2620754T3 (es) 2017-06-29
RU2541093C2 (ru) 2015-02-10
US9320743B2 (en) 2016-04-26
CA2802133A1 (en) 2012-01-12
CA2802133C (en) 2014-01-14
JP2013529657A (ja) 2013-07-22
US8809309B2 (en) 2014-08-19
US20130157993A1 (en) 2013-06-20
EP2591785A1 (en) 2013-05-15
AU2011276800A1 (en) 2013-01-10
US20140329790A1 (en) 2014-11-06
PT2591785T (pt) 2017-04-04
DK2591785T3 (en) 2017-03-27

Similar Documents

Publication Publication Date Title
BR112012030950A2 (pt) formulações de vacina
SMT201500054B (it) 2-Anilinobenzimidazolo-6-carbossammidi come agentianti-infiammattori
SMT201500291B (it) Nuovi agenti antimalarici
BR112013006016A2 (pt) compostos de azabenzotiazol, composições e métodos de uso
SMT201400055B (it) Composti di tioacetato, composizioni e metodi d'uso
BR112013029608A2 (pt) "base de liquidificador"
BR112014014547A2 (pt) compostos antagonistas de e-selectina, composições e métodos de uso
BR112012021065A2 (pt) artigo de uso descartável
DK2648809T3 (da) Naturlige formuleringer
DK2640893T4 (da) Sammensætninger
DK2590974T3 (da) Tetrahydropyridopyrimidinderivater
BR112012031861A2 (pt) uso de 5a-androstano (alquil)-3b, 5, 6b-triol
BR112013018951A2 (pt) formulações de testosterona
DK3070091T3 (da) Benzodioxolderivater som phosphodiesterasehæmmere
BR112013014612A2 (pt) composições moc
DK2343051T3 (da) Anti-cancer formulering
DK2635269T3 (da) Kombinationspræparat
BR112013009948A2 (pt) formulação de glifosato
DK2444068T3 (da) Brimonidingelpræparat
BRPI1011036A2 (pt) uso
BR112012022411A2 (pt) articulador
FR2957252B1 (fr) Composition cosmetique
FR2965705B1 (fr) Compositions d'edulcorants
DK2642980T3 (da) Pædiatrisk formulering
IT1405996B1 (it) Procedimento per la preparazione di 2,5-diaminotoluolo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/07/2011, OBSERVADAS AS CONDICOES LEGAIS.